



**FOR IMMEDIATE RELEASE**

***Peak Ridge Capital Invests in Zurex Pharma, Inc.***

MADISON, Wisconsin – May 2, 2011- Peak Ridge Capital announced today that it made investments in Zurex Pharma, Inc. and its subsidiary, Zurex PharmAgra, LLC, Madison, WI-based specialty pharma and agricultural technology companies. This investment is Wisconsin Act 255 certified and marks Peak Ridge Capital’s eleventh investment into a Wisconsin-based company. The Series A financing involves a \$1M commitment to Zurex.

Peak Ridge has a strong investment presence in Wisconsin through both their AgTech Fund and early-stage Midwest Fund. The investment in Zurex signifies the third time Peak Ridge has, as a condition of its investment, moved an early stage company to Wisconsin, or prevented its departure to another state.

Zurex Pharma has applied technology to human and agricultural markets. The core technology is an antimicrobial product platform designed to significantly reduce Healthcare Acquired Infections (HAI) by targeting surgical site infections and catheter-related bloodstream infections. Clinical trials have shown remarkable efficacy and safety results and this technology is poised to address significant unmet medical needs and provide meaningful clinical improvements for healthcare providers and patients.

Zurex PharmAgra has applied the same core technology to the dairy industry and is developing innovative products designed to prevent Mastitis in farm animals. Dairy Mastitis is a persistent inflammatory reaction of the udder tissue in cows caused by mammary gland infection. It is the most common and costly disease in dairy cattle. Mastitis is considered the primary disease affecting dairy cow milk production and results in losses exceeding \$2 billion annually.

Jason Smith, a General Partner in Peak Ridge’s AgTech Fund, commented, “Zurex has tremendous potential to prevent HAI’s and Dairy Mastitis in a way that has not been seen before. Their proprietary technology platform and near-term potential to enter highly valuable and addressable markets is very promising and we are excited about the industry prospects, as well as additional value that Peak Ridge can add to Zurex’s experienced management team.”

About Zurex Pharma:

Zurex Pharma Inc. is a medical technology and specialty pharma company focused on the development and commercialization of a portfolio of innovative products based on a proprietary, novel, antimicrobial platform. Zurex PharmAgra, LLC, a subsidiary of Zurex Pharma, applies the same antimicrobial technology to the Agricultural industry.

About Peak Ridge Capital Group:

Peak Ridge is a leading alternative asset management firm that focuses on providing truly unique investment products to its diverse investor base. Its goal is not driven by simply amassing assets under management, but rather by generating uncorrelated returns while at all times limiting overall risk and market exposure. The firm achieves this goal by bringing together the brightest minds in each specific asset class and trading strategy in an attempt to exceed its investors' expectations and desired investment objectives. The firm invests in companies with key agricultural and clean technologies that provide solutions in the areas of increasing food supply, lowering cost of production, improving efficiency in the supply chain and energy; particularly in companies based in Wisconsin.

Media contact:

Laura Small  
Peak Ridge Capital  
[www.peakridgecapital.com](http://www.peakridgecapital.com)  
(617) 425-0100

For more information about Zurex, please visit [www.Zurex-Pharma.com](http://www.Zurex-Pharma.com)

###